Filgrastim biosimilar - Sandoz

Drug Profile

Filgrastim biosimilar - Sandoz

Alternative Names: EP2006; Filgrastim Hexal (Sandoz); Filgrastim-sndz; Zarxio; Zarzio

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sandoz
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Febrile neutropenia

Most Recent Events

  • 17 May 2017 Efficacy and adverse events data from the phase III PIONEER trial in Febrile neutropenia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 26 May 2015 No recent reports of development identified - Phase-III for Febrile neutropenia (Prevention) in Russia (SC)
  • 26 May 2015 No recent reports of development identified - Phase-III for Febrile neutropenia (Prevention) in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top